shine-logo

2022

Home » 2022

Radiopharm Theranostics and SHINE Technologies Announce Clinical Supply Agreement for Cancer-Fighting Medical Isotope

SHINE to supply n.c.a. lutetium-177 for the clinical development of [...]

2022-09-20T09:07:05-05:00September 20, 2022|Safer, Healthier, News, News Releases, 2022|

SHINE Submits Drug Master File for n.c.a. Lu-177

SHINE today announced the company has submitted a Drug Master File (DMF) with the U.S. Food and Drug Administration for non-carrier-added lutetium-177 (Lu-177) chloride, a radiopharmaceutical at the forefront of precision cancer treatment.

2022-08-12T09:14:13-05:00July 29, 2022|News, News Releases, 2022|

Visit Us at the SNMMI Annual Meeting 2022

The SHINE Technologies team is gearing up for this year’s SNMMI Annual Meeting, June 11-14 in Vancouver, British Columbia. Leading molecular-imaging and nuclear-medicine professionals from every corner of the industry will come together to share in-depth views of the latest research and development, as well as share insights into practical clinical applications. 

2022-09-08T09:07:38-05:00June 10, 2022|Healthier, Blog, 2022|

SHINE CEO to Deliver Keynote at Wisconsin Entrepreneurs’ Conference 

CEO and founder Greg Piefer will give an invited presentation at the Wisconsin Entrepreneurs’ Conference in Milwaukee. On Thursday, June 2 at 8:45 a.m., Piefer will present the opening keynote before engaging in discussion with the audience.  

2022-07-25T12:50:45-05:00May 26, 2022|News, News Releases, 2022|

SHINE Announces Chris Vessell as General Manager of Therapeutics Division

JANESVILLE, Wis., May 23, 2022 – SHINE Technologies, LLC (SHINE), a next-generation nuclear technology company, today announced Chris Vessell has joined as General Manager of the Therapeutics Division. In this role, he will be responsible for developing and building the team dedicated to SHINE’s strategy and offerings around non-carrier-added lutetium-177 for cancer therapies.

2022-09-08T09:07:21-05:00May 23, 2022|Healthier, News, News Releases, Therapeutics, 2022|

SHINE and U.S. Department of Homeland Security Expand Contraband Detection

SHINE announced it has been awarded a potential 42-month contract with a total funding potential of approximately $16.8 million to help the U.S. Department of Homeland Security (DHS)

2022-04-20T12:42:30-05:00April 20, 2022|News, News Releases, 2022|
Go to Top